RESUMO
Obesity is a leading cause of preventable death and morbidity. To elucidate the mechanisms connecting metabolically active brown adipose tissue (BAT) and metabolic health may provide insights into methods of treatment for obesity-related conditions. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) is traditionally used to image human BAT activity. However, the primary energy source of BAT is derived from intracellular fatty acids and not glucose. Beta-methyl-p-iodophenylpentadecanoic acid (BMIPP) is a fatty acid analogue amenable to in vivo imaging by single photon emission computed tomography/CT (SPECT/CT) when radiolabeled with iodine isotopes. In this study, we compare the use of 18FDG-PET/CT and 125I-BMIPP-SPECT/CT for fat imaging to ascertain whether BMIPP is a more robust candidate for the non-invasive evaluation of metabolically active adipose depots. Interscapular BAT, inguinal white adipose tissue (iWAT), and gonadal white adipose tissue (gWAT) uptake of 18FDG and 125I-BMIPP was quantified in mice following treatment with the BAT-stimulating drug CL-316,243 or saline vehicle control. After CL-316,243 treatment, uptake of both radiotracers increased in BAT and iWAT. The standard uptake value (SUVmean) for 18FDG and 125I-BMIPP significantly correlated in these depots, although uptake of 125I-BMIPP in BAT and iWAT more closely mimicked the fold-change in metabolic rate as measured by an extracellular flux analyzer. Herein, we find that imaging BAT with the radioiodinated fatty acid analogue BMIPP yields more physiologically relevant data than 18FDG-PET/CT, and its conventional use may be a pivotal tool for evaluating BAT in both mice and humans.
Assuntos
Tecido Adiposo Marrom , Fluordesoxiglucose F18 , Tecido Adiposo Marrom/diagnóstico por imagem , Tecido Adiposo Marrom/metabolismo , Animais , Ácidos Graxos/metabolismo , Fluordesoxiglucose F18/metabolismo , Iodobenzenos , Camundongos , Obesidade/metabolismo , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos/metabolismo , Tomografia Computadorizada de Emissão de Fóton Único/métodosRESUMO
Currently, obesity is one of the leading causes death in the world. Shortly before 2000, researchers began describing metabolically active adipose tissue on cancer-surveillance 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in adult humans. This tissue generates heat through mitochondrial uncoupling and functions similar to classical brown and beige adipose tissue in mice. Despite extensive research, human brown/beige fat's role in resistance to obesity in humans has not yet been fully delineated. FDG uptake is the de facto gold standard imaging technique when studying brown adipose tissue, although it has not been rigorously compared to other techniques. We, therefore, present a concise review of established and emerging methods to image brown adipose tissue activity in humans. Reviewed modalities include anatomic imaging with CT and magnetic resonance imaging (MRI); molecular imaging with FDG, fatty acids, and acetate; and emerging techniques. FDG-PET/CT is the most commonly used modality because of its widespread use in cancer imaging, but there are mechanistic reasons to believe other radiotracers may be more sensitive and accurate at detecting brown adipose tissue activity. Radiation-free modalities may help the longitudinal study of brown adipose tissue activity in the future.
Assuntos
Tecido Adiposo Marrom/diagnóstico por imagem , Obesidade/diagnóstico por imagem , Acetatos/análise , Acetatos/metabolismo , Tecido Adiposo Marrom/metabolismo , Ácidos Graxos/análise , Ácidos Graxos/metabolismo , Fluordesoxiglucose F18/análise , Fluordesoxiglucose F18/metabolismo , Humanos , Imageamento por Ressonância Magnética/métodos , Imagem Molecular/métodos , Obesidade/metabolismo , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos , Tomografia por Emissão de Pósitrons/métodos , Tomografia Computadorizada de Emissão de Fóton Único/métodosRESUMO
BACKGROUND: Recent work in Pima Indians, a population with high rates of obesity and type 2 diabetes mellitus (T2DM), demonstrated that human leukocyte antigen haplotype DRB1*02 carriers have an increased acute insulin response and decreased risk for the development of T2DM, implicating loss of self-tolerance in the pathogenesis of T2DM. Advances in genomic sequencing have made T-cell receptor repertoire analysis a practical mode of investigation. METHODS: High-throughput sequencing of T-cell receptor complementarity-determining region 3 was carried out in male Pima Indians with normal glucose regulation (n = 11; age = 31 ± 8 years; %fat = 30.2 ± 8.7%) and the protective DRB1*02 haplotype versus those with T2DM without DRB1*02 (n = 7; age = 34 ± 8 years; %fat = 31.2 ± 4.7%). Findings were partially replicated in another cohort by assessing the predictive ability of T-cell receptor variation on risk of T2DM in Pima Indian men (n = 27; age = 28.9 ± 7.1 years; %fat = 28.8 ± 7.1%) and women (n = 20; age = 29 ± 7.0 years; %fat = 37.1 ± 6.8%) with baseline normal glucose regulation but without the protective haplotype who were invited to follow-up examinations as frequently as every 2 years where diabetes status was assessed by a 75-g oral glucose tolerance test. Of these subjects, 13 developed diabetes. RESULTS: T-cell receptor complementarity-determining region 3 length was shorter in those with T2DM, and a one-nucleotide decrease in complementarity-determining region 3 length was associated with a nearly threefold increase in risk for future diabetes. The frequency of one variable gene, TRBV7-8, was higher in those with T2DM. A 1% increase in TRBV7-8 frequency was associated with a greater than threefold increase in diabetes risk. CONCLUSIONS: These results indicate that T-cell autoimmunity may be an important component in progression to T2DM in Pima Indians.
Assuntos
Regiões Determinantes de Complementaridade/genética , Diabetes Mellitus Tipo 2/genética , Cadeias HLA-DRB1/genética , Polimorfismo de Nucleotídeo Único/genética , Receptores de Antígenos de Linfócitos T/genética , Adulto , Feminino , Teste de Tolerância a Glucose , Haplótipos/genética , Humanos , Indígenas Norte-Americanos , Estudos Longitudinais , MasculinoRESUMO
Androgen deprivation therapy (ADT) is a cornerstone of advanced prostate cancer (PCa) therapy. Its use is associated with a loss of bone mineral density (BMD) and a greater risk of falls and osteoporotic fractures. In this prospective cohort study, we examined the impact of ADT on muscle and bone strength in men initiating ADT for PCa. Participants were evaluated at three time points: immediately before (week 0), and 6 and 24 weeks after ADT initiation. Study measures included fasting blood levels (for markers of muscle and bone metabolic activity), MRI and QCT imaging (for muscle fat content, and bone density and architecture), and validated clinical tests of muscle strength and gait. Sixteen men completed all study visits. At baseline and throughout the study, participants exercised a median of four times/week, but still experienced weight gain (+2.0 kg at week 24 versus week 0, p = 0.004). Biochemically, all men sustained dramatic early and persistent reductions in sex hormones post-ADT, along with a progressive and significant increase in serum C-telopeptide of type I collagen (CTX, +84% at week 24 versus week 0). There was a trend for rise in serum sclerostin (p = 0.09) and interleukin 6 (IL-6) (p = 0.08), but no significant change in serum myostatin (p = 0.99). Volumetric BMD by QCT declined significantly at the femoral neck (-3.7% at week 24 versus week 0), particularly at the trabecular compartment. On MRI, there were no significant changes in thigh muscle fat fraction. On physical testing, men developed weaker grip strength, but experienced no worsening in lower extremity and lumbar spine muscle strength, or on functional tests of gait. In conclusion, in physically active men, ADT for 24 weeks results in a significant increase in bone resorption and reduction in BMD, but nonsignificant changes in thigh muscle quality (on imaging) or strength and gait (on functional testing). © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
RESUMO
Dopamine transporter SPECT is an accurate adjunct to clinical evaluation for Parkinson disease when the diagnosis is difficult. Dopaminergic medications may significantly affect dopamine transporter availability and, thus, uptake of dopamine transporter tracers. A patient had a false-positive dopamine transporter SPECT result while she was taking dextroamphetamine and amphetamine for attention-deficit hyperactivity disorder. The SPECT findings normalized after amphetamine therapy was withheld. An accurate medication history combined with knowledge of drugs that interfere with dopamine transporter imaging is critical to ensure accuracy.
Assuntos
Anfetamina/uso terapêutico , Dextroanfetamina/uso terapêutico , Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo , Tomografia Computadorizada de Emissão de Fóton Único , Reações Falso-Positivas , Feminino , Humanos , Pessoa de Meia-Idade , Doença de Parkinson/diagnóstico por imagem , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/metabolismoRESUMO
A 65-year-old woman with metastatic lung cancer was referred for CT-guided cryoablation of a right adrenal metastasis. For cryoablation, probes were placed into the adrenal region. FDG PET/CT 3 months later showed new activity in hepatic segment 6 initially suspected to be metastasis. Proximity of the hepatic lesion to the adrenal metastasis was a strange coincidence and prompted review of imaging from the cryoablation. CT showed the probe entered the liver, and postablation image demonstrated injury to the liver adjacent to the adrenal metastasis. Careful review of treatment history and imaging from ablation procedures are important to avoid this pitfall.
Assuntos
Neoplasias das Glândulas Suprarrenais/secundário , Neoplasias das Glândulas Suprarrenais/cirurgia , Artefatos , Criocirurgia , Fluordesoxiglucose F18 , Neoplasias Hepáticas/diagnóstico por imagem , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Neoplasias das Glândulas Suprarrenais/diagnóstico por imagem , Idoso , Reações Falso-Positivas , Humanos , Neoplasias Hepáticas/secundário , Neoplasias Pulmonares/patologia , MasculinoRESUMO
AIMS: Exenatide is a glucagon-like peptide 1 (GLP-1) mimetic which induces weight loss predominantly, it is presumed, via decreased food intake. However, circulating GLP-1 is also a determinant of energy expenditure. We sought to quantify the effect of exenatide on energy expenditure (EE) and energy intake. MATERIALS AND METHODS: In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4⯱â¯8.7â¯y, body fat by DXA: 44.2⯱â¯7.8%) to subcutaneous exenatide 10⯵g twice daily or placebo. Subjects were admitted to our clinical research unit for measurement of 24â¯h-EE in a whole-room indirect calorimeter and ad libitum food intake using an automated vending machine paradigm before and after randomization. Furthermore, energy expenditure and ad libitum food intake measures were repeated at 24-week after readmission for 7-day inpatient stay. Body weight was obtained weekly for up to 5â¯weeks and was recorded at each monthly follow up visit up to 24â¯weeks. RESULTS: Prior to randomization, participants over ate during the 3-day vending machine period in the whole study group (114.6⯱â¯35.2%), expressed as percentage of weight maintaining energy needs (WMEN) with those who were eventually randomized to exenatide overeating more (121.6⯱â¯37.7%) compared to placebo group (107.6⯱â¯31.5%). In the exenatide group, ad libitum absolute energy intake decreased by 1016.1⯱â¯724.5â¯kcal/day (95% CI: -1250.9 to -781.2) versus a 245.1⯱â¯710.5â¯kcal/day (95% CI: -475.4 to -14.7) decrease in placebo (Δâ¯=â¯-624.8â¯Kcal/day, pâ¯<â¯0.0001) whereas the reduction in ad libitum caloric intake relative to WMEN was a more modest 366.8⯱â¯752.1â¯kcal/day (95% CI: -614.0 to -119.6) decrease compared to 8.0⯱â¯860.1â¯kcal/day (95% CI: -286.8 to 270.8) reduction in placebo (Δâ¯=â¯-382.3â¯Kcal/day, pâ¯=â¯0.03). The decrease was uniform across all macronutrients groups. No differences in 24hEE or substrate oxidation rates were found. In the exenatide group, body weight decreased more over the 5â¯weeks (ßâ¯=â¯-0.039â¯kg/week, pâ¯=â¯0.02) and was lower compared to placebo at the end of fifth week (-1.48⯱â¯0.77â¯kg; 95% CI: -3.02 to 0.05, pâ¯=â¯0.06). At the 24-week follow up, there was no difference in energy intake between exenatide group and placebo group and the treatment group decreased 24-h EE more compared to placebo (ßâ¯=â¯-160.6â¯Kcal/day, 95% CI: -307.6 to 13.6, pâ¯=â¯0.03) compared to their pre-randomization measurement. However, this reduction was not present after adjustment for changes in FM and FFM (ßâ¯=â¯-87â¯kcal/day, pâ¯=â¯0.14). No difference was observed in body weight (Δâ¯=â¯-1.72â¯kg, 95% CI: -5.77 to 2.30, pâ¯=â¯0.39) in exenatide versus placebo over 24â¯weeks. CONCLUSION: Compared with placebo, exenatide decreased early ad libitum energy intake but did not change 24â¯h-EE. However, the reduction was more modest in relative versus absolute terms (i.e. below that needed for WMEN). Thus, although rate of weight change was greater in the exenatide treated subjects at 5â¯weeks, the absolute difference in weight was not significant. These findings indicate that although exenatide reduces food intake, it may be more beneficial in blunting overeating and thus may serve to more prevent weight regain following initial weight loss.
Assuntos
Fármacos Antiobesidade/farmacologia , Ingestão de Energia/efeitos dos fármacos , Metabolismo Energético/efeitos dos fármacos , Exenatida/farmacologia , Obesidade/tratamento farmacológico , Adulto , Fármacos Antiobesidade/uso terapêutico , Índice de Massa Corporal , Método Duplo-Cego , Exenatida/uso terapêutico , Feminino , Humanos , Masculino , Resultado do TratamentoRESUMO
Parastomal gallbladder herniation is a rare complication of enterostomies with only 6 previously reported cases. Most cases have occurred in elderly women. Patients typically presented with acute abdominal pain and the majority was managed operatively. Here, we report the clinical course of an 88-year-old female who presented with signs of sepsis and minimal abdominal symptoms. She was subsequently found to have a parastomal gallbladder herniation and Klebsiella pneumoniae bacteremia. Given the patient's multiple comorbidities, she was managed nonoperatively with manual reduction of the parastomal hernia and antibiotics.
RESUMO
OBJECTIVE: To assess the association of adipocyte size with cellular lipolysis and between cellular lipolysis and whole-body lipid oxidation. This study also assessed the association between adipocyte size and cellular lipolysis with weight and fat mass gain. METHODS: Subjects had assessment of percent body fat (%fat) and adipose tissue biopsy for in vitro lipolysis (n = 325), and a subset of subjects had measurement of whole-body lipid oxidation (n = 112). A subset of subjects (n = 243) returned for repeated measurements of body weight and composition (mean follow-up 8.2 ± 5.5 years). RESULTS: In vitro lipolysis (r = 0.47, P < 0.0001) and adipocyte size (r = 0.49, P < 0.0001) were strongly associated with %fat. In vitro lipolysis (P = 0.04) but not adipocyte size (P = 0.44) was associated with whole-body fat oxidation. Adipocyte size was not associated with rate of percent weight gain (P = 0.20) but was negatively associated with rate of percent fat mass gain (P = 0.01). In vitro lipolysis was negatively associated with rate of percent weight gain (P = 0.02) and had a marginal negative association with rate of percent fat mass gain (P = 0.08). CONCLUSIONS: These results indicate inherent characteristics of adipocytes, including size and lipolytic activity, may be important determinants of whole-body lipid oxidation and subsequent weight gain.
Assuntos
Adipócitos/citologia , Lipólise/fisiologia , Oxirredução , Aumento de Peso , Adulto , Composição Corporal , Peso Corporal , Estudos Transversais , Metabolismo Energético , Feminino , Seguimentos , Humanos , Masculino , Adulto JovemRESUMO
Chronic Budd-Chiari syndrome can present with cirrhosis and signs and symptoms similar to those of other chronic liver diseases. We present a case of Budd-Chiari syndrome discovered during attempted transjugular intrahepatic portosystemic shunting in a patient with decompensated cirrhosis believed to be secondary to hepatitis C. Although the patient had hepatocellular carcinoma, the Budd-Chiari syndrome was a primary disease due to hepatic venous webs. Angioplasty was performed in this case, which resolved the patient's symptoms related to portal hypertension. Follow-up venography 5 months after angioplasty demonstrated continued patency of the hepatic veins. A biopsy was obtained in the same setting, which showed centrilobular fibrosis indicating that venous occlusion was indeed the cause of cirrhosis. It is important to consider a second disease when treating a patient with difficult to manage portal hypertension.
RESUMO
BACKGROUND: Chordoma is a rare invasive bone tumor that may occur anywhere along the neuraxis. A total of three primary histological varieties have been identified: conventional, chondroid, and dedifferentiated. CASE PRESENTATION: We report a case of an 8-year-old white girl who presented with conventional chordoma, was treated with surgical resection and mixed proton and photon beam therapy, and had a recurrence in the resection cavity 2.5 years later with dedifferentiated morphology. The recurrent tumor did not express brachyury, a recently identified protein specific to tissue of notochordal origin. CONCLUSIONS: The short time period between radiation therapy and dedifferentiation, low dose of photons, and rarity of dedifferentiated skull base chordomas in pediatric patients should alert clinicians to the possibility of chordoma dedifferentiation after proton beam therapy.
Assuntos
Desdiferenciação Celular/efeitos da radiação , Cordoma/patologia , Imageamento por Ressonância Magnética , Recidiva Local de Neoplasia/patologia , Terapia com Prótons , Radioterapia Adjuvante , Sarcoma/diagnóstico por imagem , Neoplasias da Base do Crânio/patologia , Biomarcadores Tumorais , Desdiferenciação Celular/fisiologia , Linhagem Celular Tumoral , Criança , Cordoma/diagnóstico por imagem , Cordoma/terapia , Feminino , Humanos , Recidiva Local de Neoplasia/cirurgia , Doses de Radiação , Sarcoma/patologia , Neoplasias da Base do Crânio/diagnóstico por imagem , Neoplasias da Base do Crânio/terapiaRESUMO
In this study, we develop a classification system for describing polymethyl methacrylate (PMMA) spread in vertebral bodies after kyphoplasty or vertebroplasty for vertebral compression fractures (VCFs) and for assessing whether PMMA spread varies between operators, VCF etiology, or vertebral level. Intraoperative fluoroscopic images of 198 vertebral levels were reviewed in 137 patients (women, 84; men, 53; mean age, 75.8 ± 12.5; and those with a diagnosis of osteoporosis, 63%) treated with kyphoplasty between January 01, 2015 and May 31, 2015 at a single center to create a 5-class descriptive system. PMMA spread patterns in the same images were then classified by 2 board-certified radiologists, and a third board-certified radiologist resolved conflicts. A total of 2 primary PMMA spread patterns were identified, namely, acinar and globular, with subtypes of localized acinar, diffuse globular, and mixed, to describe an equal combination of patterns. Interrater reliability using the system was moderate (κ = 0.47). After resolving conflicts, the most common spread class was globular (n = 63), followed by mixed (n = 58), diffuse globular (n = 30), acinar (n = 27), and localized acinar (n = 20). The spread class after treatment by the 2 most frequent operators differed significantly (n1 = 63, n2 = 70; P < .0001). There was no difference in the spread class between VCF etiologies or vertebral levels. PMMA spread may, therefore, be a modifiable parameter that affects kyphoplasty and vertebroplasty efficacy and adverse events.